Abstract
The topoisomerase-1 inhibitor, topotecan, was tested in 48 eligible patients with advanced colorectal cancer. The patients had no prior chemotherapy and a Southwest Oncology Group performance status of 0-2. Topotecan was administered intravenously at 1.5 mg/m2/day for five days and repeated every 21 days. The major toxicity was hematologic with 19 out of 48 (40%) patients having grade IV granulocytopenia and 4 out of 48 (8%) patients demonstrating grade IV thrombocytopenia. Two patients (4%) demonstrated partial response. Thirty patients have died and the Kaplan-Meier estimate of median survival is 9 months (95% confidence interval, 7-16 months). Topotecan in this dose and schedule does not appear active in patients with advanced colorectal cancer.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 357-359 |
| Number of pages | 3 |
| Journal | Investigational New Drugs |
| Volume | 15 |
| Issue number | 4 |
| DOIs | |
| State | Published - 1997 |
| Externally published | Yes |
Fingerprint
Keywords
- Colorectal cancer
- Topoisomerase-1 inhibitor
- Topotecan
ASJC Scopus subject areas
- Molecular Medicine
- Pharmacology
Cite this
Phase II evaluation of topotecan in patients with advanced colorectal cancer. A Southwest Oncology Group trial (SWOG 9241). / Macdonald, John S.; Benedetti, Jacqueline K.; Modiano, Manuel; Alberts, David S.
In: Investigational New Drugs, Vol. 15, No. 4, 1997, p. 357-359.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Phase II evaluation of topotecan in patients with advanced colorectal cancer. A Southwest Oncology Group trial (SWOG 9241)
AU - Macdonald, John S.
AU - Benedetti, Jacqueline K.
AU - Modiano, Manuel
AU - Alberts, David S
PY - 1997
Y1 - 1997
N2 - The topoisomerase-1 inhibitor, topotecan, was tested in 48 eligible patients with advanced colorectal cancer. The patients had no prior chemotherapy and a Southwest Oncology Group performance status of 0-2. Topotecan was administered intravenously at 1.5 mg/m2/day for five days and repeated every 21 days. The major toxicity was hematologic with 19 out of 48 (40%) patients having grade IV granulocytopenia and 4 out of 48 (8%) patients demonstrating grade IV thrombocytopenia. Two patients (4%) demonstrated partial response. Thirty patients have died and the Kaplan-Meier estimate of median survival is 9 months (95% confidence interval, 7-16 months). Topotecan in this dose and schedule does not appear active in patients with advanced colorectal cancer.
AB - The topoisomerase-1 inhibitor, topotecan, was tested in 48 eligible patients with advanced colorectal cancer. The patients had no prior chemotherapy and a Southwest Oncology Group performance status of 0-2. Topotecan was administered intravenously at 1.5 mg/m2/day for five days and repeated every 21 days. The major toxicity was hematologic with 19 out of 48 (40%) patients having grade IV granulocytopenia and 4 out of 48 (8%) patients demonstrating grade IV thrombocytopenia. Two patients (4%) demonstrated partial response. Thirty patients have died and the Kaplan-Meier estimate of median survival is 9 months (95% confidence interval, 7-16 months). Topotecan in this dose and schedule does not appear active in patients with advanced colorectal cancer.
KW - Colorectal cancer
KW - Topoisomerase-1 inhibitor
KW - Topotecan
UR - http://www.scopus.com/inward/record.url?scp=0031424630&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0031424630&partnerID=8YFLogxK
U2 - 10.1023/A:1005941603420
DO - 10.1023/A:1005941603420
M3 - Article
C2 - 9547679
AN - SCOPUS:0031424630
VL - 15
SP - 357
EP - 359
JO - Investigational New Drugs
JF - Investigational New Drugs
SN - 0167-6997
IS - 4
ER -